← FDA DRUG APPROVALS

FDA ANDA · ANDA214729

ETYQA

estradiol and norethindrone acetate

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA214729
TYPE
ANDA
ORIGINAL APPROVAL
2023-06-30
LATEST ACTION
2025-06-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ETYQADiscontinued
ESTRADIOL 0.5MG, NORETHINDRONE ACETATE 0.1MG · TABLET · ORAL
ETYQADiscontinued
ESTRADIOL 1MG, NORETHINDRONE ACETATE 0.5MG · TABLET · ORAL

Approval history

2025-06-20Labeling · Supplement 1 · standardAP
2023-06-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →